^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GCT02

i
Other names: GCT02
Associations
Trials
Company:
Myrio Therap
Drug class:
EGFRvIII-targeted CAR-T immunotherapy
Associations
Trials
over1year
Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma. (PubMed, Clin Transl Immunology)
Here, we show our de novo generated, high-affinity EGFRvIII-specific CAR; GCT02, demonstrating curative efficacy in human orthotopic glioblastoma models...This study demonstrates the preclinical functionality of a highly specific CAR targeting EGFRvIII on human cells. This CAR could be an effective treatment for glioblastoma and warrants future clinical investigation.
Journal • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
GCT02